US EditionPublished • loading... • Updated
Ocugen Completes Dosing in Stargardt Disease Gene Therapy Trial
Summary by MyChesCo
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Ocugen Completes Dosing in Stargardt Disease Gene Therapy Trial
MALVERN, PA — Ocugen Inc. (Nasdaq: OCGN) has completed enrollment and dosing in its Phase 2/3 clinical trial evaluating a gene therapy candidate for Stargardt disease. The GARDian3 trial enrolled 63 patients and was completed in less than nine months, according to the company. Topline results are expected in the second quarter of 2027, with a planned Biologics License Application submission by mid-2027. The study is evaluating OCU410ST, a modifi…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
